



**Eligibility criteria for  
WHO prequalification of in vitro diagnostics**

*Prequalification of in vitro diagnostics, March 2025  
update*

## WHO/MHP/RPQ/PQT/2025.3

© World Health Organization 2025

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** Eligibility criteria for WHO prequalification of in vitro diagnostics, Prequalification of in vitro diagnostics, March 2025 update. Geneva: World Health Organization; 2025 (WHO/MHP/RPQ/PQT/2025.3). Licence: [CC BY-NC-SA 3.0 IGO](#).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <https://iris.who.int/>.

**Sales, rights and licensing.** To purchase WHO publications, see <https://www.who.int/publications/book-orders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

## Contents

1	Introduction .....	1
2	Intended audience .....	1
3	Eligibility for prequalification of IVDs .....	2
3.1	Original manufacturer .....	2
3.2	Rebranded products .....	2
3.3	Commercial availability .....	2
3.4	Eligibility principles .....	2
3.5	Eligibility criteria .....	2
4	Relevant documents .....	4
5	Contact information .....	4

## 1 Introduction

World Health Organization (WHO) prequalification of in vitro diagnostics (IVDs) is coordinated through the Regulation and Prequalification department. Focus is placed on IVDs for priority diseases and their suitability for use in resource-limited settings.

WHO prequalification of IVDs is a comprehensive quality assessment of individual IVDs through a standardized procedure aimed at determining whether a product meets WHO prequalification requirements.

The full prequalification assessment process includes the following components:

- review of a full product dossier;
- performance evaluation, including operational characteristics;
- manufacturing site(s) inspection; and
- labelling review.

An abridged prequalification assessment includes the following components:

- review of an abridged product dossier;
- performance evaluation, including operational characteristics;
- manufacturing site(s) inspection; and
- labelling review.

Products submitted for prequalification assessment that meet, as determined by WHO, the WHO prequalification requirements are included in the WHO list of prequalified IVDs. The duration of the validity of the prequalification status of a product is dependent on the manufacturer's fulfilment, within the applicable deadlines, of its post-qualification obligations and requirements, including:

- prequalification commitments;
- annual reporting;
- reporting of changes;
- post-market surveillance obligations;
- undergoing routine inspections; and
- ongoing compliance with WHO prequalification technical specification series documents.

The findings of WHO prequalification<sup>1</sup> are used to assess the safety, quality and performance of commercially available IVDs for the purpose of providing guidance to interested United Nations (UN) agencies and WHO Member States in their procurement decisions.

## 2 Intended audience

This document has been prepared to provide manufacturers and other stakeholders with an overview of the eligibility criteria applied to products submitted for WHO prequalification assessment of IVDs. It is recommended that manufacturers wishing to apply for WHO prequalification of their product(s) read this document before applying for prequalification.

---

<sup>1</sup> Prequalification does not imply any approval by WHO of the product and manufacturing site(s). Moreover, prequalification does not constitute any endorsement or warranty by WHO of the fitness of any product for a particular purpose, including its safety, quality or performance.

## 3 Eligibility for prequalification of IVDs

### 3.1 Original manufacturer

Applications for WHO prequalification of IVDs are accepted only from the legal manufacturer of the product.<sup>2</sup>

### 3.2 Rebranded products

WHO is aware that several manufacturers purchase finalized products from other companies, and then "rebrand" and place these products on the market under their own name or brand. Such products are also known as original equipment manufacturer (OEM) products.

WHO considers a rebranded product to be one that is manufactured under identical conditions at the same manufacturing site(s) as the original product. In other words, a rebranded product is identical in every respect (including the intended use) to the product manufactured by the original manufacturer, except that the product is labelled with the rebranded product name and product code and bears the rebrander's name or brand.

Rebranded products are outside the scope of prequalification, and hence are not accepted for prequalification assessment.

### 3.3 Commercial availability

Applications for WHO prequalification of IVDs are only accepted for products that are commercially available at the time of submission for prequalification assessment. Any exemptions must be agreed upon by WHO prior to the submission of the application for prequalification.

### 3.4 Eligibility principles

To meet the needs of WHO Member States and UN agencies, the prequalification scope is defined according to the following prequalification eligibility principles:

- Need for IVDs for a particular disease or disease state;
- Appropriateness of the product for use in resource-limited settings;
- Requests from WHO Member States for particular IVDs;
- Recommendation in WHO disease specific testing guidelines; and
- Availability of prequalified products that are of a similar assay format and/or assay principle.

### 3.5 Eligibility criteria

The eligibility principles are applied using the following eligibility criteria:<sup>3</sup>

- Products that are manufactured by original product manufacturers<sup>4</sup>;
- Products that are commercially available when submitted for prequalification assessment;

---

<sup>2</sup> The definition of a manufacturer is based on the definition used by the Global Harmonization Task Force (GHTF), and later adopted by the International Medical Device Regulators Forum (IMDRF). This internationally accepted approach has been adopted to ensure that there is a clear understanding of the term "manufacturer" across international markets. For further details see: <http://www.imdrf.org/>

<sup>3</sup> WHO reserves the right to apply other criteria dependent on changing global health needs, the particular needs of WHO Member States, and the emergence of new and relevant technologies.

<sup>4</sup> Re-branded products are not accepted for prequalification assessment

- Products of interest to UN organizations and other procurement agencies;
- Product categories for which there exists few other prequalified products<sup>5</sup>.

The Prequalification team currently accepts the following applications:

**Table 1: Products currently eligible for prequalification assessment<sup>6</sup>**

Function of the test	Technology
<b>HIV</b>	
Diagnosis of infection	Rapid diagnostic tests Enzyme immunoassays Nucleic acid tests
Self testing	Rapid diagnostic tests
Monitoring of infection	Flow cytometer for enumeration of lymphocyte subset including CD4+ T cells, or a technology that can be used at or near the patient Nucleic acid tests for measuring viral load
<b>Hepatitis C virus</b>	
Diagnosis of infection	Rapid diagnostic tests Enzyme immunoassays
Aid to diagnosis of infection and monitoring of anti-viral therapy	Nucleic acid tests
<b>Hepatitis B virus</b>	
Diagnosis and monitoring of infection	Rapid diagnostic tests Enzyme immunoassays
Monitoring of infection and anti-viral therapy	Quantitative nucleic acid tests
<b>Malaria parasites</b>	
Diagnosis of infection	Rapid diagnostic tests
<b>Human papilloma virus</b>	
Diagnosis of infection (for cervical cancer prevention)	Nucleic acid tests
<b>Glucose-6-phosphate dehydrogenase (G6PD) enzyme</b>	
Enzyme deficiency detection	Technologies/formats to be used at or near the patient
<b>Toxigenic <i>Vibrio cholerae</i></b>	
Detection of outbreaks or surveillance for the disease	Rapid diagnostic tests
<b><i>Treponema pallidum</i> (Syphilis)</b>	
Screening and aid to diagnosis of infection	Rapid diagnostic tests
<b><i>Mycobacterium tuberculosis</i> complex and resistance to first and/or second line anti-tuberculosis drugs</b>	
Diagnosis of infection	Qualitative nucleic acid tests
<b>SARS-CoV-2</b>	

<sup>5</sup> This document only applies to IVD medical devices. Male circumcision devices' assessment eligibility criteria are defined in a separate document.

<sup>6</sup> See technical specification series documents for more detail available on our website <https://extranet.who.int/prequal/vitro-diagnostics/technical-specifications-series>

Diagnosis of infection	Rapid diagnostic tests Qualitative nucleic acid tests
<b>Blood glucose</b>	
Monitoring of diabetes	Handheld systems
<b>HbA1c</b>	
Monitoring response to therapy in people with diabetes or as an aid to diagnosis of type 2 diabetes	Point of care analysers
<b>Haemoglobin</b>	
Screening for/diagnosis of anaemia, aid in the diagnosis of anaemia, aid in diagnosis of severe anaemia in patients with malaria, Monitoring of haemoglobin levels	Point of care analysers

The eligibility criteria are reviewed and amended in consultation with WHO Member States, other UN agencies, WHO programmes and technical experts.

The prequalification pre-submission form and supportive documentation will be reviewed against the above criteria to determine eligibility for prequalification assessment. If the product meets the WHO prequalification eligibility criteria the manufacturer will be informed on the next steps to be followed depending on the type of assessment (full or abridged) applicable to the product.

#### 4 Relevant documents

The following WHO Prequalification of IVD documents provide information to guide the manufacturer through the requirements of the prequalification assessment:<sup>7</sup>

- Overview of the WHO prequalification of in vitro diagnostics assessment: Document PQDx\_007;
- Pre-submission form: Document PQDx\_015;
- Instructions for the completion of the pre-submission form: Document PQDx\_017.

#### 5 Contact information

Any inquiries regarding WHO prequalification of IVDs should be addressed to: [diagnostics@who.int](mailto:diagnostics@who.int)

<sup>7</sup> These documents are available through the following website: <https://extranet.who.int/prequal/vitro-diagnostics/prequalification-guidance>